8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 12, 2007

HELIX BIOMEDIX, INC.

(Exact name of registrant as specified in its charter)

DELAWARE	033-20897-D	91-2099117
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(IRS Employer Identification No.)

22118 20th Avenue SE, Suite 204

Bothell, Washington 98021

(425) 402-8400

(Address and telephone number of registrant’s principal executive offices)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01        Entry into a Material Definitive Agreement.

On September 12, 2007, Helix BioMedix, Inc. (the “Company”) entered into a First Amended and Restated License Agreement (the “Amended Agreement”) with Grant Industries, Inc., which amends and restates the Non-Exclusive License Agreement between the parties dated December 12, 2006. Among other things, the amendments included in the Amended Agreement render the license thereunder to a certain Company peptide exclusive, add an additional Company peptide to the scope of the license grant thereunder, also on an exclusive basis, and expand the scope of the licensed territory to include certain countries in Asia.

A copy of the press release announcing entry into the Amended Agreement is being filed as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01        Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press release, dated September 17, 2007, issued by Helix BioMedix, Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	HELIX BIOMEDIX, INC.
Dated: September 17, 2007	By:	/s/ David H. Kirske
		David H. Kirske
		Vice President and Chief Financial Officer

EX-99.1

Exhibit 99.1

Helix BioMedix and Grant Industries advance collaborative partnership for
innovative application of cosmetic peptide technology

Bothell, WA; Elmwood Park, NJ — September 17, 2007 — Helix BioMedix, Inc. (OTCBB: HXBM) and Grant Industries, Inc. announced today a modification of a license agreement that makes Grant Industries the exclusive licensee of two anti-aging peptides, palmitoyl-Hexapeptide-6 and Hexapeptide-21.

“We’ve been impressed with Grant’s vision for these two peptides,” commented R. Stephen Beatty, President and CEO of Helix BioMedix, Inc. “Their appreciation of the breadth of potential for palmitoyl-Hexapeptide-6 in particular has taken it beyond being just an ingredient and evolving it as a platform technology that has many beneficial applications in the marketplace.”

David Granatell, Executive Director of Grant Industries, concurs. “Our objective has been to tailor ingredient blends and application formats with Helix’s peptides to help brand marketers leverage the technology in ways that are consistent with their unique positions in the marketplace. We’ve applied palmitoyl-Hexapeptide-6 in some very creative formulations and have even been able to instill anti-aging peptide benefits to cosmetic powders through a proprietary process we’ve developed. These anti-aging formulas are in addition to a product line we’ve formulated with Helix’s patented Oligopeptide-10, a cosmetic ingredient for acne-prone skin.”

Today, Grant’s ingredient blends with palmitoyl-Hexapeptide-6 may be found in a variety a forms from skin care creams, lotions and serums, to liquid make-up foundations and mineral powders. Proprietary products containing the peptide are currently sold in mass, prestige and direct response channels by leading brand marketers. According to Granatell, “numerous new products that apply the peptide are under development for launch in 2007 or 2008 in the U.S., Canada, Asia, and Europe.”

About Helix BioMedix, Inc.

Helix BioMedix, Inc. is a biopharmaceutical company with an extensive library of diverse bioactive peptides and patents covering six distinct classes and hundreds of thousands of peptide sequences. More information about Helix BioMedix and its proprietary peptides may be found on the company’s website at www.helixbiomedix.com.

About Grant Industries, Inc.

Grant Industries is a family owned company involved in the research, development, manufacturing, and marketing of specialty chemicals for the cosmetic, textile, and printing industries.

Forward-Looking Statements

This press release contains forward-looking statements regarding Helix BioMedix, Inc. (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding activities, events or developments that Helix BioMedix, Inc. expects, believes or anticipates may occur in the future, including statements related to its potential growth, product development and commercialization and revenue. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company’s ability to successfully raise additional capital, enter into revenue generating license agreements, continue its research and development efforts, including pre-clinical and clinical studies, continue developing marketable peptide-based products and general economic conditions. Additional assumptions, risks and uncertainties are described in detail in the company’s reports and other filings with the Securities and Exchange Commission. Such filings are available on the Helix BioMedix, Inc. website or at www.sec.gov. Readers are cautioned that such forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. Helix BioMedix, Inc. undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.

Helix BioMedix Contacts:

Investor Contact:
Ryan Bright
Shelton Group Investor Relations
(972) 239-5119 X 159
rbright@sheltongroup.com

Company Contact:
R. Stephen Beatty
President and CEO
(425) 402-8400
sbeatty@helixbiomedix.com

Grant Industries Contacts:

Company Contact:
Paul Granatell
Executive Director
(201) 791-8700
pgranatell@grantinc.com